

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
22 November 2001 (22.11.2001)

PCT

(10) International Publication Number
WO 01/87272 A2

(51) International Patent Classification⁷: **A61K 9/28**

(US). YOO, Jaedeok [US/US]; 107 Primrose Court, Belle Mead, NJ 08502 (US).

(21) International Application Number: PCT/US01/40763

(22) International Filing Date: 18 May 2001 (18.05.2001)

(74) Agents: **BETCHER, Susan, D.** et al.; Seed Intellectual Property Law Group PLLC, Suite 6300, 701 Fifth Avenue, Seattle, WA 98104-7092 (US).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/205,896 18 May 2000 (18.05.2000) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(71) Applicants (*for all designated States except US*): **THERICS, INC.** [US/US]; 115 Campus Drive, Princeton, NJ 08540 (US). **MASSACHUSETTS INSTITUTE OF TECHNOLOGY** [US/US]; 77 Massachusetts Avenue, Cambridge, MA 02139 (US).

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **PAYUMO, Francis, C.** [US/US]; 192 High Street, North Andover, MA 01845 (US). **WANG, Chen-Chao** [—/US]; 20 Highmont Drive, West Windsor, NJ 08550 (US). **SHERWOOD, Jill, K.** [US/US]; Apartment 5, 308 Trinity Court, Princeton, NJ 08540 (US). **CIMA, Michael, J.** [US/US]; 184 Mystic Valley Parkway, Winchester, MA 01890 (US). **GAYLO, Christopher, M.** [US/US]; 22 Landing Lane, Princeton Junction, NJ 08550 (US). **MONKHOUSE, Donald, C.** [US/US]; 439 King of Prussia Road, Rednor, PA 19087


Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHOD AND FORM OF A DRUG DELIVERY DEVICE, SUCH AS ENCAPSULATING A TOXIC CORE WITHIN A NON-TOXIC REGION IN AN ORAL DOSAGE FORM

Tablet Design



(57) Abstract: A drug delivery device such as an oral dosage form (ODF) with a toxic or potent core encapsulated by a non-toxic region. The non-toxic region may be a region including multiple layers, coatings, shells, and combinations thereof, which provides protection to and isolation from the toxic or potent core. The drug in the toxic or potent core is incorporated into the dosage form via, for example, three-dimensional printing, as a solution, solubilization or suspension of solid particles in liquid, rather than by the more conventional handling and compressing of dry powder.

This minimizes the likelihood of creating airborne particles of the toxic drug during manufacturing, hence controlling and minimizing the exposure of manufacturing personnel to the hazardous substance. Wet dispensing of the toxic or potent drug further provides greater bioavailability of the drug to the patient.

WO 01/87272 A2

METHOD AND FORM OF A DRUG DELIVERY DEVICE, SUCH AS
ENCAPSULATING A TOXIC CORE WITHIN A NON-TOXIC REGION IN AN
ORAL DOSAGE FORM

TECHNICAL FIELD

5 This invention relates generally to pharmaceutical delivery systems and more particularly to an oral dosage form including a non-toxic region encapsulating or surrounding a pharmaceutically toxic or potent core.

BACKGROUND OF THE INVENTION

10 Oral dosage forms (ODFs) of drugs have previously been surrounded by a coating that had properties different from the properties of the interior. For example, coated tablets were the subject of U.S. Patent No. 5,914,132, within which the coating allowed delivery of the drug to the colon, with its particular chemical environment, rather than in an earlier part of the gastrointestinal tract with its different chemical environment, such as pH and enzymatic system.

15 Methods and apparatus for coating pharmaceuticals were disclosed in U.S. Patent No. 4,497,847, which disclosed methods for applying the coating to the pharmaceutical via spraying or immersing in a centrifugal fluidized coating apparatus or a fluidized bed granulating coating apparatus. These coatings were intended to provide various controlled-release profiles. Most commonly the main interior part of
20 the tablet was formed by compression of powder.

 In these and similar patents, the drug was not especially toxic or hazardous, and the coating did not serve the purpose of isolating the toxic or hazardous substance from personnel who manufacture or handle the product. Therefore, no unusual handling or manufacturing precautions beyond those ordinarily employed in the
25 pharmaceutical industry were necessitated due to the properties of the drug. Furthermore, the coating process was usually performed on finished tablets or pellets that had been manufactured by a separate process, and not concurrent with the manufacture of the pharmaceutical form. Therefore, the coating process itself did not

circumvent the powder-mixing step during manufacture, in which airborne particulate matters could be generated. Airborne particulate matters of highly toxic or potent pharmaceuticals created problems for manufacturing personnel and non-patient personnel that required special handling procedures. These procedures have often been
5 both ineffective and expensive.

Soft gelatin capsules have been used to deliver actives in dissolved, solubilized, or suspended forms. Soft gelatin capsules have the advantages of avoiding exposure to airborne hazardous particles as well as achieving better content uniformity than other solid dosage forms. However, migration of solute and the actives from the
10 liquid phase to the gelatin shell have been a major drawback. Soft gelatin capsules were also not suitable for formulation of actives which require long release duration, since the capsule itself did not sustain drug release. Soft gelatin capsules have therefore not been used with a drug that was highly toxic, potent or otherwise hazardous.

Some pharmaceuticals, such as anti-cancer drugs, are highly toxic. For
15 example, 9-nitrocamptothecin is used to treat pancreatic cancer, and yet is so toxic that companies are unwilling to manufacture it into solid dosage forms because of the exposure danger inherent in conventional manufacturing techniques. There are also other types of pharmaceutical actives, such as hormones, that are so potent that non-patient personnel must not be exposed to even small quantities of them. Thus, there is a
20 need for manufacturing techniques and ODFs which are better suited to the handling, both during and after manufacture, of substances which are highly toxic or potent or otherwise hazardous to non-patients.

One attempt to address handling issues of toxic components during manufacturing of ODFs was disclosed in WO 94/09762. The active ingredient was in
25 liquid form and was applied to the core of the ODF as a film coating, and which was optionally surrounded by an overcoating for further isolation. This manufacturing technique involved a substantial number of sequential manufacturing steps and could only incorporate the amount of drug that was contained in the one thin layer that the liquid coating formed around the central form. Drugs that had low solubility were thus
30 precluded.

Three dimensional printing (3DP) techniques have been used to manufacture medical devices as disclosed in U.S. Patent Nos. 5,490,962; 5,869,170; and 5,518,680. However, 3DP manufacturing of medical devices failed to overcome many of the post processing steps, such as applying a coating, that were found in conventional manufacturing. Additionally, 3DP manufacturing of medical devices required a final step of removing and dedusting the medical device from the loose unbound powder in the powder bed. Dedusting removed some powder particles at the surface of the medical device that were not securely bound to the main body of the product. Dedusting included agitation applied to the medical device to remove loose powder particles and partially bound particles. When manufacturing a medical device with a hazardous material, loose powder particles can be problematic to the manufacturer. Furthermore, varying dedusting techniques may result in variations in drug quantity.

SUMMARY OF THE INVENTION

The present invention overcomes the limitations of the prior art and provides additional benefits. Under one aspect of the present invention, a pharmaceutical delivery system such as an oral dosage form (ODF) includes a hazardous drug encapsulated by a non-toxic region. This non-toxic region may be a pharmacologically inert substance and is a region such as a layer, a coating, or a shell that provides an isolation barrier between the toxic or potent interior and exterior contact.

Another aspect of the present invention includes a manufacturing technique by which the toxic drug is incorporated into the individual ODF as a solution, aqueous suspension, or by solubilization, rather than by the more conventional compression of powder. This minimizes the likelihood of creating airborne particles of the toxic drug during manufacturing, hence controlling and minimizing the exposure of manufacturing personnel to the toxic compounds. Incorporating the drug as a solution, solubilization or aqueous suspension further allows greater bioavailability of the drug to the patient.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is an isometric view of a three dimensional printing apparatus in accordance with one embodiment of the invention.

Figure 2 is an exploded isometric view of a pharmaceutical form in
5 accordance with one embodiment of the invention.

Figure 3 is a partially exploded isometric view of the pharmaceutical form of Figure 2 in accordance with one embodiment of the invention.

Figure 4 is a section view of a pharmaceutical form illustrating a buffer region within an individual printed layer in accordance with one embodiment of the
10 invention.

Figure 5 is an elevation view of the pharmaceutical form of Figure 4 along line 5-5 further illustrating the buffer region above and below the core region.

Figures 6A-6B are a detailed printing diagram corresponding to Example 1 including individual drop locations or voxels.

15 Figures 7A-7E are figures illustrating various pharmaceutical forms corresponding to Example 2 including individual regions for two different drugs.

DETAILED DESCRIPTION OF THE INVENTION

A drug delivery device, and in particular, a method for manufacturing a pharmaceutical in the form of an oral dosage form (ODF) with a toxic or potent drug
20 encapsulated by a non-toxic region wherein the non-toxic region may be a pharmacologically inert substance. The non-toxic region provides an isolation barrier or buffer zone protecting the toxic or potent core from damage during handling or from early release of the drug. The non-toxic substance is fabricated to encapsulate the core with a region that includes an unbound region of powder, a layer of non-toxic drug, a
25 coating, a shell, or any combination thereof. The toxic drug may be incorporated into the delivery device as a solution, suspension, or by solubilization, which serves to minimize toxic airborne particles while providing greater bioavailability of the drug to the patient. In the following description, numerous specific details are provided, such as a manufacturing technique by which the toxic drug is put into the individual ODFs as

a solution, suspension, or by solubilization, rather than by handling loose powder. One skilled in the relevant art, however, will recognize that the invention can be practiced without one or more of the specific details, or with other actives or inert substances. In other instances, well-known structures, operations or processes are not shown or not
5 described in detail to avoid obscuring aspects of the invention.

One manufacturing technique suitable for making the dosage form of the present invention is of the family known as Solid Free-form Fabrication (SFF). SFF involves building up arbitrary shapes from powder, for example, with Three Dimensional Printing or with Selective Laser Sintering, or from a liquid or paste, for
10 example, with Stereolithography. One SFF process is Three-Dimensional Printing (3DP) described in U.S. Patent No. 5,204,055 issued to Emanuel Sachs et al.

As illustrated in Figure 1, a 3DP apparatus includes a printer 100 including a first axis 110 of movement, a second axis 120 of movement which may be perpendicular to the first axis of movement 110, and a liquid dispensing device 130.
15 The dispensing device 130 can dispense drops 140 of a first liquid onto a powder bed 150. The layer of powder 150 is laid down, by a roller or other method such as slurry deposition. Liquid is dispensed onto predetermined regions of the powder bed by the dispensing device 130 for dispensing small quantities of liquid drops 140, typically resembling an ink-jet printhead. For example, it could be a microvalve (Lee Company,
20 Essex, CT) or it could be a piezoelectric drop-on-demand printhead as is known in the art. This causes particles of the powder bed 150 in the wetted regions to fuse or bind together, either by dissolution and resolidification or by the adhesive action of the liquid drops 140. Sometimes a powdered binder is included in the powder bed 150 and when it is exposed to liquid drops 140 it binds other particles. After this liquid dispensing
25 process is completed on one layer, another layer of powder is spread and the liquid dispensing is repeated, and so on until a complete three-dimensional object has been built.

During printing, the unbound powder supports the bound shape and the later deposited layers of powder. At the end of the printing process the unbound and
30 untrapped powder is removed, leaving only the shape which has been bound together.

At each powder layer, timing of drop ejection is coordinated, for example by software, with the motion of the printhead in two axes 110, 120, to produce almost any desired shape of bound product potentially including details of great complexity.

For applications such as the present one, it may be further desirable to
5 include a second dispenser 132 for dispensing drops 142 of a second liquid. The second dispenser 132 is shown as being mounted on the same motion system and printhead as the first dispenser 130. Alternatively, the second dispenser 132 could be mounted on a separate motion system. If the second dispenser 132 is separately mounted, it may be preferable to provide a system of suitable registration or coordination locating the two
10 dispensers 130, 132, so that each dispenser can deposit liquid in a predetermined location accurately relative to the location of liquid deposited by the other dispenser.

The present invention is directed toward pharmaceutical dosage forms, for example, oral dosage forms (ODFs). ODFs typically include a bulk material, a binder and an active agent. The powder or bulk material may be composed of typical
15 pharmaceutical excipients such as are known in the art. Examples of excipients include but are not limited to microcrystalline cellulose, lactose, mannitol and dicalcium phosphate.

Binder is dispensed onto the bulk material. Binder may be a liquid, a powder or some combination of a liquid and a powder referred herein as a slurry or a
20 suspension. Binder may further be a liquid containing solubilized active. By solubilization, compounds that are typically insoluble can form micelles to increase the solubility in the dispersing system when surfactant or solubilizer is added to the system. Surfactants form aggregates of molecules or ions called micelles when the concentration of the surfactant solute in the bulk of the solution exceeds a limiting
25 value, the so-called critical micelle concentration (CMC). The formation of micelles is referred to herein as a solubilization process.

One possible purpose of the binder is to carry the drug or active agent to the delivery system. Another possible purpose is to cause particles to bind to each other, in which case it is referred to herein as a binding agent. The binder may further
30 serve both of these functions or some portion thereof. Binding of the particles can

occur through several mechanisms. One mechanism is that the binder is a liquid that acts as a solvent of the bulk material or powder, in which case the liquid actually dissolves powder particles. As the solvent in the liquid evaporates, the particles resolidify such that they are joined together. Another mechanism is that the liquid
5 binder simply solidifies around solid particles thereby binding them. Yet another mechanism is that the liquid binder may contain a dissolved adhesive substance that is left behind when the liquid evaporates to bind the particles together. The dissolved substance may be a plasticizer, for example, a polymeric material, which modifies the chemistry of the bulk material to cause bonding. Plasticizers are incorporated into a
10 polymer to increase its workability, flexibility, or distensibility by increasing the free volume between the polymer molecules. The increase in free volume will increase the freedom of movement for polymer molecules and therefore provide better fusing between polymer particles. Plasticizers are usually moderately high molecular weight liquids, or occasionally, low melting solids. Examples of commonly used plasticizers
15 include, but are not limited to, carboxylic acid and phosphoric acid esters. Yet another mechanism for binding includes the powder bulk material containing particles of a binder in solid form that are activated upon absorption of certain solvents.

In the present application, the active agent or drug is deposited in a central region or core of the dosage form. A liquid containing toxic or potent drug is
20 herein referred to as the core binder. This is shown in Figure 1 as a liquid drop 140 containing a pharmaceutical active being dispensed to place a drug or a combination of drugs in specified regions of the powder bed 150. The core binder preferably functions as a binding agent, thus causing powder particles to adhere together, but it is not essential that it function as a binding agent. The liquid may simply serve as a means of
25 placing the drug within the dosage form.

In accordance with one embodiment of the present application, there is a second liquid 142 concurrently dispensed to form an encapsulated region around the region containing the active. The second liquid 142 serves as a binding agent to bind the powder or bulk material and creates the region encapsulating the hazardous core.
30 This second liquid is herein referred to as the shell binder. The shell binder does not

contain a toxic or potent drug although it may contain an active drug with other therapeutic purposes.

The shell binder may include a non-toxic active that is complementary to the toxic drug in the core region, a pre-treatment to the drug in the core, or even counteractive to a feature of the drug in the core. For example, an anti-cancer drug in the core could be paired with an anti-emetic or anti-vomiting drug placed in the shell binder. Other examples of additives or actives that may be incorporated in the shell binder include taste-masking actives, sugar, additives to increase the physical integrity and reduce friability of the dosage form, or additives to delay the release of the core drug based on pH of environment or based on duration of ingestion.

Figures 2 and 3 illustrate ODFs 200 and 300 in which a box or shell encloses the active core. In Figure 2, individual layers of the ODF 200 are exploded apart for clarity of illustration. A top 210, a bottom 220 and walls 240 surround core 230, which contains a toxic or potent drug. In any individual layer where drug is deposited, a non-toxic region 240 forms a closed curve around the region in which drug has been deposited. This non-toxic region can be a pharmaceutically inert substance or a region containing therapeutic but non-toxic drugs. Top and bottom 210 and 220 also form non-toxic regions. Considering all three dimensions, all of the non-toxic closed curves or regions on individual layers taken together form a non-toxic enclosing surface region or shell. This non-toxic region acts as a boundary or isolation region between the toxic core and the handlers and may include multiple regions including transition regions, layers, coatings, shells, or combinations thereof.

Figure 3 illustrates an ODF similar to Figure 2, but with simpler construction. The top of the box 310 and the bottom of the box 320 are shown in an exploded view. In this embodiment, the walls are constructed as a thickened layer. In this figure the active hazardous core 330 is shown surrounded by the top 310, the bottom 320 and walls 340.

One exemplary method of manufacturing the dosage form in accordance with the present invention is by building one or more bottom layers with a drug-free or non-toxic binder in the shape of the intended geometry of the dosage form. Subsequent

layers would include concurrently or sequentially dispensed toxic core drug placed within the footprint of the bottom layers and drug-free or non-toxic binder fluid placed around an encapsulating perimeter of the toxic core.

5 The walls 240, 340 are formed by binding together portions of powder, again using the non-toxic shell binder, to define a closed region on the sides, including all areas surrounding the toxic core which are not already bounded by the bottom or top. The walls 240, 340, as well as the top and bottom 210, 310, 220, 320, may be referred to as the shell, and the binder which binds the walls 240, 340 and top 210, 310 and bottom 220, 320 may be referred to as the shell binder.

10 In one embodiment, powder in an intermediate or transition region between the shell and the core is not bound together but is trapped in place between the core and the shell. Alternatively, the transition region 230, 330 shown as the walls 240, 340 of the dosage form in Figures 3 and 4 may include multiple regions of bound and unbound powder including non-toxic pharmaceutical excipients or other inert
15 substances.

The walls 240, 340 at each layer are further bound to the bound region of the layer below it and the layer above it, thus encapsulating the toxic core. The layers above and below may be layers in which the shape of the shell boundary is printed or may be the top or bottom. A top for the box may be created in much the same way as the
20 bottom.

The illustrated embodiment produces an enclosure that is a hollow rectangular parallelepiped. However, it should be recognized that any other shape, for example, a cylinder, ellipsoid, rod, or sphere, could also be produced. Any of these shapes could further be placed, either singly or in a group, inside a capsule.

25 Pharmaceuticals incorporating a powder are characterized by friability, namely, the tendency for particles of the surface to rub off or break off from attrition during processing or handling. Friability is a measure of fragility. In the present invention, if such breaking off of particles does occur, such particles are the non-toxic exterior surface of the dosage form. This represents a significant advantage over the
30 prior art. However, it is still desirable that the completed device not be excessively

friable. If the device were extremely friable, the particles may break off to expose the toxic core. The friability will be determined by the composition of the shell. Accordingly, the composition of the shell, namely the powder and shell binder, should be selected so that the finished product has at least a moderate amount of resistance to
5 chipping, breakage, attrition, friction, and the like. Material selections for achieving this are known in the art and are further described in the Examples.

The core binder and optionally the shell binder may contain a pharmaceutical active as a dissolved solute. Alternatively, either of these binders may be a suspension containing solid particles of the drug suspended in the liquid, if for
10 example, the drug is not sufficiently soluble in the liquid being used. In yet another embodiment, the binder may contain an active in solubilized form.

Wet dispensing of the toxic or potent drug in a solution, microfine suspension, or in solubilized form allows a solid dosage form to include a toxic or potent drug in an amorphous state. Providing a drug in an amorphous state is
15 advantageous because it results in a drug with higher bioavailability to the patient than a drug that is allowed to exist in a crystalline form. Drugs in an amorphous, non-crystalline state are better absorbed by the body than drugs in a crystalline state due to the higher surface area for dissolution and absorption.

Yet another advantage of the present invention is that when the drug is in
20 amorphous form with the presence of crystallization inhibitors, crystal growth can be inhibited, thus enhancing the absorption of the drug. Steric hindrants, such as PVPs, HPMCs, or surfactants in a binder solution that contains the active will inhibit the recrystallization of the active in the dosage form after drying. Therefore, the resolidified active particles will either be in amorphous form or have very small crystal size. As a
25 result, the absorption will be enhanced as compared to the original solid state of the active because the increase in surface area for the dissolution and hence absorption will enhance the bioavailability of the drug.

Another factor relevant to achieving isolation of the toxic core relates to bleeding. Bleeding is the spreading of liquid in the powder bed after the liquid is
30 printed but before it dries. Bleeding occurs by capillary action, and is a common

concern in 3DP because it affects dimensional accuracy and surface finish. Bleeding can occur in the horizontal direction in a powder layer and in the vertical direction into previous or subsequent layers of powder. Bleeding in the vertical direction is less of a concern and as stated previously, will serve to bind subsequent layers together.

5 Typically in 3DP, all of the printed regions on a layer are at least somewhat wet simultaneously. This contributes to the time efficiency of the process and to better interlayer adhesion between printed regions on adjacent layers. However, bleeding becomes a concern if it draws the toxic or potent pharmaceutical active closer to the surface than might be expected, resulting in poorer isolation than designed. For

10 example, if the core and shell regions are printed approximately simultaneously and touch each other, the liquid in the two wet regions may intermix. This would result in the spread of the toxic or potent active beyond the geometric location where it was intended to be positioned.

One method of counteracting bleeding is to include a transition region in

15 the dosage form. Therefore the toxic or potent active can spread without causing a problem or without actually reaching the shell binder. The transition region can be an encapsulating region around the toxic core that contains unbound powder, partially bound powder or bound powder.

Figure 4 illustrates one embodiment of the present invention in which

20 the pharmaceutical form 400 includes a transition region 410. The transition region 410 is created between the drug-containing core 420 and the shell region 430 to absorb the possible bleeding or infiltration of the drug-containing liquid beyond the core region 420 where the drug-containing drops were actually placed. The transition region 410 thus prevents the toxic or potent drug from reaching or infiltrating into the shell. This is

25 further illustrated in Example 1.

The transition region 410 can be constructed from unbound powder. In such a situation the toxic or potent core 420 would be innermost, the walls 430 of the box would be outermost, and between them would be a thin buffer region 410 which is not bound together and also does not contain a toxic or potent drug like the innermost

region. If bleeding of the toxic or potent drug occurs, such bleeding could spread into the buffer or transition region 410 but would not actually reach the wall or shell 430.

As shown in Figure 5, one or more layers of powder above the bottom layer and one or more layers of powder just below the top layer allows the
5 encapsulation of the toxic core 420 by the transition region 410. No core binder would be printed into these layers. This would provide opportunity to absorb possible bleeding in the vertical direction. This further helps achieve isolation of the drug or the hazardous core 420 from the outside world.

Another method of controlling bleeding is to appropriately select the
10 excipients making up the powder. There are substances that may be included in the powder that form a gel when they absorb the binder liquid. Since the binder liquid is absorbed and immobilized, the gel will function as an infiltration barrier, with the result that the binder liquid does not spread further after it has interacted with this substance. An example of such a substance is hydroxypropylmethylcellulose (HPMC). Other
15 examples for use with aqueous binder solution include polyvinyl alcohols (PVAs), polyethylene glycols, polyethylene oxides, carbopols, hydrophilic silica gel, xanthan gum, gellan gum, locust bean gum, acrylic acid polymers, gelatin, sodium carboxymethyl cellulose, methylcellulose, guar gum, sodium alginate, polyethylene-polypropylene copolymer, corn starch, and polyvinyl pyrrolidones (PVPs) and other
20 hydrophilic polymers. Other examples for use with ethanolic binder systems include polyethylene glycols, polyethylene-polypropylene copolymers, polyoxyethylene alkyl ethers, polyvinyl pyrrolidones, and the like.

In conventional manufacturing of pharmaceuticals, it is the powder-handling steps which offer relatively great likelihood of dispersing quantities of
25 substances where they are not wanted. Powders can be difficult to contain because powders include a range of particles sizes and the fine particles can become easily airborne. One advantage of the present invention, wherein the toxic or potent drugs are wet dispensed, is that the powder which is spread to form each layer can be composed of pharmacologically inert excipients, and so any particulates that might be dispersed
30 from it are benign. In the present invention, the toxic or potent drugs are contained in

the liquid that is dispensed. The hazardous substance can be liquid-dispensed even if it is non-soluble or only slightly soluble in the liquid, because if necessary the substance can be contained in the liquid as a suspension of solid particles, or in solubilized form. By virtue of this, it is possible to avoid the tendency found in tablet pressing techniques for particles of dry powder containing drug to become airborne, which in the case of highly toxic or potent substance can present an exposure hazard to manufacturing personnel.

An additional advantage over the prior art is that the present invention provides encasement of toxic or potent drugs without contact of the toxic or potent drugs by either personnel or tooling. Furthermore, the dosage forms themselves do not bump into or touch each other during manufacturing. Non-contact of the dosage forms during manufacturing makes both the product and the process an improvement over previous techniques.

The finished form of the present invention is a solid which effectively immobilizes the toxic or potent pharmaceutical active that is in the core region with the encapsulating intermediate or transition region. This is a more complete immobilization than would be the case for an alternative packaging of a soft gel capsule, where liquid is surrounded by a gelatin shell. In a soft gel capsule there still can be a finite rate of diffusion of substances from the interior liquid into the surrounding capsule body.

This has the further advantage that when a 3DP dosage form is dedusted as described earlier, the possible dislodging of partially adhered particles from the surface of the dosage form does not remove any toxic drug, and hence dedusting cannot introduce any errors in the dosage of drug contained in individual dosage forms. This eliminates a possible randomizing influence on the final content of drug in the dosage form.

Figures 7A-7E illustrate a further embodiment of the present invention illustrating a dosage form that will release in two doses. This embodiment can be used to include two doses of an active in one single unit dosage form to enhance patient compliance and reliability. The first dose included in the shell region 730 can be

immediately released upon administration. The transition region 720 between the shell region and the core region 710 can be fabricated with a high saturation level to generate a lag time. An example of this design is to include an anti-cancer compound and an anti-emetic compound in a single dosage form. Thus, the anti-emetic contained in the
5 shell region 730 can have sufficient time to take effect before treatments resulting in nausea such as an anti-cancer treatment are administered. In this case the transition region 720 would be bound through the use of a binder which is a binding agent and which forms a time-delay region. This might be a third binder beyond the two already disclosed. Alternatively, for such a dosage form the design could be as follows, starting
10 from the outside and progressing inward: a shell region containing an anti-emetic; an interiorly-located shell which is a time delay; a transition region which could be unbound powder for bleeding control; and a core region containing the toxic or potent drug; with all regions encapsulating the region immediately adjacent and interior to them.

15 The following examples are further provided for illustrative purposes.

EXAMPLE 1

Drugs of particular interest are camptothecin (C₂₀ H₁₅ N₃ O₆) and its derivative, 9-nitrocamptothecin (9-NC) (rubitecan), and also other derivatives of camptothecin. These drugs are effective against pancreatic cancer, which is a
20 particularly virulent form of cancer. 9-NC has an oral LD-50 (for mice) of 55 mg/kg acute, 2.5 mg/kg chronic. It is considered extremely dangerous to handle. In fact, its toxicity is part of what makes it useful against cancer. Despite the drugs' known effectiveness, drug manufacturers and packagers are reluctant to manufacture solid ODFs using the drug because of its toxicity and potential hazard to manufacturing
25 personnel. If a conventional uncoated tablet of this pharmaceutical were made by tablet-pressing methods, airborne particulates would be a significant hazard to manufacturing and packaging personnel, and direct contact with the tablets would be a hazard to nurses, pharmacists, and other healthcare personnel. Because of this, the drug is relatively unavailable to patients, even though they have little other available
30 treatment.

The oral dosage form in the present example was made using the 3DP process. The liquid used in dispensing this drug was an aqueous suspension. The drugs are essentially insoluble in water. Microfine camptothecin or 9-NC was incorporated into the suspension at a concentration of 2.5% (by weight). The average particle size was approximately 0.5 microns. Other substances included in the suspension were Avicel RC-591 (10% Na CMC, 90% microcrystalline cellulose) and PVP K-25 (polyvinyl pyrrolidone of a molecular weight of 25,000 g/mole), which function as a suspending agent and steric hindrant to prevent agglomerate formation, respectively. Drops were dispensed by electronically actuated microvalves made by the Lee Corporation, Essex CT, through nozzles which were holes drilled through jewels as are commercially available from the Swiss Jewel Company, Philadelphia PA. Dispensing by other methods, as are known in the art, could also be used.

The powder which was used to make the ODF matrix (the powder upon which printing was performed) was a mixture containing hydroxypropylmethyl cellulose (HPMC) and other excipients, such as Avicel CL-611, Avicel PH-301 and lactose. Avicel is manufactured by the FMC Corp., Philadelphia, PA. Avicel CL-611 contains 85% of microcrystalline cellulose and 15% of sodium carboxymethyl cellulose (Na CMC). Na CMC functions as a solid binder that gels upon hydration. Avicel PH-301 is a type of microcrystalline cellulose, a water-insoluble excipient. HPMC is a gelation agent as already described. The quantity of HPMC can be varied to adjust the drug release rate. Addition of more HPMC effectively decreases the drug release rate. Flow rates of drug suspensions were adjusted to deliver a nominal total drug loading of 0.5 mg active to the core region of the ODF.

Typical dimensions of tablets 600, shown in Figure 6A, were 4.8 mm diameter and 12.1 mm long, so as to be able to fit inside a #3 capsule. Printing parameters such as number of voxels (unit cells) in various directions are shown in Figure 6B. The dimension of a voxel corresponds somewhat to the dimension of a drop and also is influenced by the degree of saturation (filling of void spaces by liquid) desired. For the manufacturing pattern shown here, a typical unit spacing in the horizontal direction is 10 microns. The shell region 630 was fabricated with a binder (dispensed liquid) (shell

binder) which was a drug-free solution containing PVP (polyvinyl pyrrolidone) and Tween 20 (polyethylene sorbitan-monolaurate, Sigma Chemical Co., St. Louis, MO) which provided appropriate viscosity and surface tension of the liquid. A colorant, FD&C Red No. 40, was also added. The binding of the exterior surfaces (bottom, top and walls) was achieved with this liquid.

Figure 6B illustrates an important feature of the product design. A buffer region 620 between the core region 610 and the shell region 630, as has already been discussed. The buffer region 620 is occupied by powder which is not printed upon by either the core binder or the shell binder. This provides space into which the core (drug-containing) binder can bleed if needed, without actually reaching the shell. This improves the degree of isolation of the toxic or potent substance from the outside world. In the printing pattern shown here, the dimension of the buffer region 620 in the horizontal direction is one voxel or drop spacing distance or one spatial increment in the slow axis direction. In the vertical direction, similar isolation was provided by printing the bottom surface, and then leaving two or three powder layers with no printing by the core binder, before beginning to print the core binder. In this case the thickness of a powder layer was 400 microns. Because of gravity, bleeding vertically downward (to a previously deposited powder layer) is more serious than is bleeding vertically upward (to a subsequently deposited powder layer). Accordingly, at the top of the printed dosage form, it is possible to similarly leave one or more layers of powder with no core binder printed onto them, but the importance or the required thickness is not so great as it is on the bottom.

Various combinations of excipient types, HPMC (hydroxypropylmethyl cellulose) content and the microstructure of the dosage form matrix were produced by alteration of the fabrication parameters. These various combinations resulted in various different drug release rates. Drug release rates were determined by a USP basket method using 0.1N HCl with or without the presence of surfactant, e.g., sodium lauryl sulfate. A typical drug release duration of a non-encased oral dosage form would be 10 minutes. However, slower initial release rate would be preferable because the irritation by the active to stomach will be minimized. It was found that the drug release duration

could be prolonged from 10 minutes to two hours or longer by varying the excipient types. Drug release could be further retarded by increasing HPMC level, e.g., approximately 40% of drug was released at one hour when HPMC content was increased to 50%. The presence of the shell can also have effects on the drug release rate, depending on the shell's thickness, composition, etc., although in this case it was not intended that the shell have significant effect on the release profile.

The packaging of this ODF was such that after manufacture of the dosage form, it was intended that the ODF would be encapsulated with hard shell capsules. Capsules typically come in two halves which slide together forming a close fit. They are typically made of a gelatinous material which dissolves rather quickly in the fluids of the gastrointestinal tract. The dimensions of the dosage form, being 12.1 mm long and 4.8 mm in diameter, lend themselves to fitting inside a #3 capsule.

EXAMPLE 2

Other drugs of interest are thyroid hormones, triiodothyronine (T3) (molecular weight = 650.98 g/mole) and tetraiodothyroxine (T4) (molecular weight = 776.87 g/mole). These are hormones which are even more potent per unit mass than the previously described anti-cancer drug. Similar to anti-cancer drugs, hormones have the concern of unwanted personnel exposure to the actives during processing and hence require isolation from personnel who manufacture and handle the product. This example illustrates a different category of drug, namely hormones. For certain therapeutic purposes, these two hormones would need to be included in a single oral dosage form. Thus, this example also illustrates an extra detail of manufacturing beyond Example 1, namely the creation of two geometric drug regions instead of just one. In this example the dispensed liquid is a solution rather than a suspension. The desired drug loading in a tablet is a dosage of T4 per tablet in the range of 25 to 200 micrograms, and a dosage of T3 per tablet in the range of 1.5 to 12 micrograms.

Figures 7A-7E illustrate various pharmaceutical forms. Two different shapes are shown here, Figure 7D and 7E, one which is appropriate for later insertion inside capsules, and one which is appropriate for tablets without the need of encapsulation. In the capsule geometry, the length is the longest dimension of the

dosage form, and so the preferred geometric arrangement of the two individual drug regions is for them to be stacked on top of each other and both enclosed inside a pharmacologically inert shell. For the tablet geometry, the diameter is the largest dimension of the dosage form, and again all the active would have to be surrounded by
5 an inert shell, but it might be preferable to locate one drug region concentrically inside the other drug region, with both of them further being surrounded by the pharmacologically inert shell.

Dispensing of the drug in liquid form would be by techniques similar to those in Example 1, except that for these particular drugs it would probably not be
10 necessary to use a suspension because the combination of the solubility of the drug and the required dosage is such that the needed dosage can be dissolved in the binder liquid.

In the examples presented herein, the example shapes were some form of prism, for example, a cylinder or a rectangular parallelepiped, and therefore all shapes had a flat bottom and a flat top and some shape of sides which filled in the rest of the
15 closed boundary. However, it can well be appreciated that one strength of 3DP in general is its ability to produce complex shapes. Thus, there is no need to limit dosage form shape to shapes having a flat top and bottom. 3DP would be perfectly capable of printing a dosage form which is spherical, or ellipsoidal, or cylindrical with curved top and bottom, or other shape.

20 The present invention has been discussed in terms of drops of liquid being dispensed. However, it should be understood that in some situations, liquid may be dispensed in ways which are not exactly discrete drops. For example, liquid may be dispensed as a series of lumps of fluid which are connected to each other by narrow strings of liquid. Liquid may even be dispensed as streams which are simply turned on
25 and off or even are physically interrupted by masks. All of these are covered by the present invention. The dispensed liquid may be an aqueous (water-based) liquid as previously disclosed, but it could also be in general any liquid formulation including water, ethanol, other alcohols, chloroform, other halogenated hydrocarbons, acetone, etc., and combinations thereof as appropriate.

The present invention has been discussed in terms of 3DP, which is a prime candidate for manufacturing. However, 3DP is only one of a number of technologies known collectively as solid free-form fabrication (SFF). Other members of this family could also be used.

5 The ODF can also be further enclosed by a capsule if desired for ease of administering to patients or for appearance or marketing purpose. The capsule could contain either one or a plurality of ODF's manufactured as described herein. A further embodiment could include a coating for purposes of taste, aesthetic appearance or reduced friability.

10 The invention has been described with respect to toxic anti-cancer drugs and potent hormones, but it could similarly be used with any other toxic or potent compounds with toxicity or potency hazard concerns, such as other anti-cancer drugs, other hormones, steroids, or narcotics.

15 In Example 1, the shell was not intended to perform any function as far as determining the release rate of the drug. It was made of a substance which would dissolve fairly quickly after being swallowed. However, in other applications it might be useful to design the composition and dimensions of the shell so as to cause the shell to influence the release profile in a desired way, as is known in the art, for example, as described in WO98/3673941.

20 The above description of illustrated embodiments of the invention is not intended to be exhaustive or to limit the invention to the precise form disclosed. While specific embodiments of, and examples for, the invention are described herein for illustrative purposes, various equivalent modifications are possible within the scope of the invention, as those skilled in the relevant art will recognize. The teachings provided
25 herein of the invention can be applied to other pharmaceutical forms, possibly even to implantable drug delivery devices, not only to the exemplary oral dosage forms described above.

 The various embodiments described above can be combined to provide further embodiments. All of the above patents and applications are incorporated by
30 reference. Aspects of the invention can be modified, if necessary, to employ the

process, apparatuses and concepts of the various patents and applications described above to provide yet further embodiments of the invention.

These and other changes can be made to the invention in light of the above detailed description. In general, in the following claims, the terms used should
5 not be construed to limit the invention to the specific embodiments disclosed in the specification and the claims, but should be construed to include all pharmaceuticals that operate under the claims to provide a method for containing a hazardous core. Accordingly, the invention is not limited by the disclosure, but instead the scope of the invention is to be determined entirely by the following claims.

CLAIMS

1. A pharmaceutical dosage form, comprising:
a core region containing a first toxic or potent pharmaceutical active;
a transitional region wherein the transitional region encapsulates the core region; and
a shell region wherein the shell region encapsulates the transitional region and wherein the shell region is not toxic or potent.
2. The pharmaceutical dosage form of claim 1 wherein the transitional region includes unbound powder.
3. The pharmaceutical dosage form of claim 1 wherein the first toxic or potent pharmaceutical active is dispensed as a solution or a suspension or by solubilization.
4. The pharmaceutical dosage form of claim 1, further including a second toxic or potent active contained in the core region independent from the first toxic or potent active.
5. The pharmaceutical dosage form of claim 4 wherein the second toxic or potent active encapsulates the first toxic or potent active.
6. The pharmaceutical dosage form of claim 1 wherein the first pharmaceutical active is an anti-cancer drug, a steroid, a hormone, a narcotic or another compound having a high toxicity or potency.
7. The pharmaceutical dosage form of claim 1 wherein the first pharmaceutical active is camptothecin or 9-nitrocamptothecin or triiodothyronine or tetraiodothyroxine.

8. The pharmaceutical dosage form of claim 1 wherein the shell region is pharmaceutically inert.

9. The pharmaceutical dosage form of claim 1 wherein the shell region includes one or more pharmaceutical excipients.

10. The pharmaceutical dosage form of claim 1, further comprising a capsule that completely surrounds the shell region.

11. The pharmaceutical dosage form of claim 1 wherein the shell region includes a release-controlling substance.

12. A pharmaceutical dosage form manufactured by three-dimensional printing comprising:

a core region containing at least one toxic or potent pharmaceutical contained in a first liquid deposited on a powder bed;

a transitional region wherein the transitional region encapsulates the core region; and

a shell region wherein the shell region encapsulates the transitional region, wherein the shell region is non-toxic and wherein the shell region comprises a second liquid deposited on the powder bed.

13. The pharmaceutical dosage form of claim 12 wherein the toxic or potent pharmaceutical is dissolved in the first liquid.

14. The pharmaceutical dosage form of claim 12 wherein the toxic or potent pharmaceutical is present in the first liquid as suspended particles.

15. The pharmaceutical dosage form of claim 14 wherein the average size of the suspended particles is approximately 0.5 micron or less.

16. The pharmaceutical dosage form of claim 14 wherein the first liquid is dispensed through an orifice having a diameter, and the maximum size of the suspended particles is less than approximately one-tenth the diameter of the orifice.

17. The pharmaceutical dosage form of claim 14 wherein the suspension further comprises a steric hindrant or a suspending agent or both.

18. The pharmaceutical dosage form of claim 12 wherein the device is made from powder that is one or more pharmaceutical excipients.

19. The pharmaceutical dosage form of claim 18 wherein the powder further comprises a gelatin agent that forms a gel when it interacts with the first liquid, whereby the migration of first liquid through the powder is slowed.

20. The pharmaceutical dosage form of claim 19 wherein the gelation agent comprises hydroxypropylmethylcellulose or other hydrophilic polymer.

21. The pharmaceutical dosage form of claim 12 wherein the shell region includes a release-controlling substance.

22. The pharmaceutical dosage form of claim 12 further comprising a capsule that completely surrounds the shell.

23. The pharmaceutical dosage form of claim 12 wherein the second liquid is a solvent for a powder in the powder bed.

24. The pharmaceutical dosage form of claim 12 wherein the second liquid comprises adhesive or plasticizer.

25. The pharmaceutical dosage form of claim 12 wherein the powder comprises solid particles of an adhesive that interacts with the first or the second liquid.

26. A method of manufacturing a pharmaceutical delivery device comprising a core region containing a pharmaceutical active and a shell region surrounding the core region, comprising:

spreading a layer of powder;

dispensing a first fluid containing a pharmaceutical active onto the powder in selected places forming a core region;

dispensing a second fluid onto the powder in places such as to completely surround the places where the first fluid is deposited and forming a shell region; and

repeating the process as many times as needed, wherein the first liquid is dispensed only into a region that is encapsulated by the surrounding shell region formed by the second liquid.

27. The method of claim 26 wherein the first or the second liquid further include a binding agent.

28. The method of claim 26 wherein the pharmaceutical active is a anti-cancer drug, a steroid, a hormone, a narcotic, or another compound having high toxicity or potency.

29. The method of claim 26 wherein the pharmaceutical active is camptothecin or 9-nitrocamptothecin or other derivatives of camptothecin or triiodothyronine or tetraiodothyroxine.

30. The method of claim 26 wherein the first liquid contains the pharmaceutical active in solution.

31. The method of claim 26 wherein the first liquid contains the pharmaceutical active as solid particles suspended in the first liquid.

32. A method of manufacturing a dosage form containing an encapsulated toxic or potent core, comprising: dispensing a first binder fluid which contains neither a toxic or potent excipient onto a layer of bulk material; dispensing a second binder fluid containing a toxic or potent active within the footprint of the first binder fluid on at least one subsequent layer of bulk material; dispensing a binder fluid which contains neither a toxic or potent excipient around a perimeter region of the dispensed toxic binder on the at least one subsequent layer of bulk material wherein the perimeter region is bound to the adjacent layer; dispensing a binder fluid which contains neither a toxic or potent excipient over at least one subsequent layer of bulk material thereby enclosing the toxic or potent binder region with an encapsulating region which contains neither a toxic or potent excipient.

1/6








Fig. 1

*Fig. 2*

3/6

12 *Fig. 3*

4/6

*Fig. 4**Fig. 5*

5/6




Fig. 6A




Fig. 6B

6/6




Fig. 7A




Fig. 7B




Fig. 7C




Fig. 7D




Fig. 7E

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
22 November 2001 (22.11.2001)


PCT

(10) International Publication Number
WO 01/87272 A3

- (51) International Patent Classification⁷: **A61K 9/28**
- (21) International Application Number: **PCT/US01/40763**
- (22) International Filing Date: **18 May 2001 (18.05.2001)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:
60/205,896 **18 May 2000 (18.05.2000)** **US**
- (71) Applicants (for all designated States except US): **THER-ICS, INC.** [US/US]; 115 Campus Drive, Princeton, NJ 08540 (US). **MASSACHUSETTS INSTITUTE OF TECHNOLOGY** [US/US]; 77 Massachusetts Avenue, Cambridge, MA 02139 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **PAYUMO, Francis, C.** [US/US]; 192 High Street, North Andover, MA 01845 (US). **WANG, Chen-Chao** [—/US]; 20 Highmont Drive, West Windsor, NJ 08550 (US). **SHERWOOD, Jill, K.** [US/US]; Apartment 5, 308 Trinity Court, Princeton, NJ 08540 (US). **CIMA, Michael, J.** [US/US]; 184 Mystic Valley Parkway, Winchester, MA 01890 (US). **GAYLO, Christopher, M.** [US/US]; 22 Landing Lane, Princeton Junction, NJ 08550 (US). **MONKHOUSE, Donald, C.** [US/US]; 439 King of Prussia Road, Rednor, PA 19087 (US). **YOO, Jaedeok** [US/US]; 107 Primrose Court, Belle Mead, NJ 08502 (US).
- (74) Agents: **BETCHER, Susan, D. et al.**; Seed Intellectual Property Law Group PLLC, Suite 6300, 701 Fifth Avenue, Seattle, WA 98104-7092 (US).
- (81) Designated States (national): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.**
- (84) Designated States (regional): **ARIPO** patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), **Eurasian** patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), **European** patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), **OAPI** patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**
- with international search report
 - before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report:
18 April 2002
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **ENCAPSULATING A TOXIC CORE WITHIN A NON-TOXIC REGION IN AN ORAL DOSAGE FORM**

Tablet Design



(57) Abstract: A drug delivery device such as an oral dosage form (ODF) with a toxic or potent core encapsulated by a non-toxic region. The non-toxic region may be a region including multiple layers, coatings, shells, and combinations thereof, which provides protection to and isolation from the toxic or potent core. The drug in the toxic or potent core is incorporated into the dosage form via, for example, three-dimensional printing, as a solution, solubilization or suspension of solid particles in liquid, rather than by the more conventional handling and compressing of dry powder. This minimizes the likelihood of

creating airborne particles of the toxic drug during manufacturing, hence controlling and minimizing the exposure of manufacturing personnel to the hazardous substance. Wet dispensing of the toxic or potent drug further provides greater bioavailability of the drug to the patient.

WO 01/87272 A3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/40763

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K9/28

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 659 432 A (AKZO NOBEK N.V.) 28 June 1995 (1995-06-28) page 2, line 8 - line 27 page 4 -page 6; examples 1,3 ----	1,3,6,8, 9
X	EP 0 671 167 A (TANABE SEIYAKU CO., LTD.) 13 September 1995 (1995-09-13) page 6; example 1 ----	1,2,6,8, 9,11
A	WO 98 36739 A (THERICS, INC.) 27 August 1998 (1998-08-27) cited in the application the whole document page 20; example 3 ----	12-32
A	WO 94 09762 A (MERCK & CO., INC.) 11 May 1994 (1994-05-11) page 1, line 10 -page 2, line 21 -----	1-32



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

22 February 2002

Date of mailing of the international search report

01/03/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Benz, K

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/40763

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 659432	A	28-06-1995	EP 0659432 A1	28-06-1995
			AT 155039 T	15-07-1997
			AU 685538 B2	22-01-1998
			AU 8168494 A	29-06-1995
			CA 2138451 A1	24-06-1995
			CN 1108929 A	27-09-1995
			DE 69404116 D1	14-08-1997
			DE 69404116 T2	13-11-1997
			DE 659432 T1	30-01-1997
			DK 659432 T3	16-02-1998
			ES 2105501 T3	16-10-1997
			FI 946043 A	24-06-1995
			GR 3024817 T3	30-01-1998
			JP 7206681 A	08-08-1995
			NO 944991 A	26-06-1995
			NZ 270228 A	26-09-1995
			US 5662936 A	02-09-1997
			ZA 9409929 A	23-08-1995
EP 671167	A	13-09-1995	JP 7223970 A	22-08-1995
			CA 2142142 A1	11-08-1995
			CN 1116926 A	21-02-1996
			EP 0671167 A1	13-09-1995
			US 5614220 A	25-03-1997
WO 9836739	A	27-08-1998	AU 733676 B2	24-05-2001
			AU 6177198 A	09-09-1998
			EP 1014950 A1	05-07-2000
			JP 2001515472 T	18-09-2001
			US 6280771 B1	28-08-2001
			WO 9836739 A1	27-08-1998
WO 9409762	A	11-05-1994	AU 5592694 A	24-05-1994
			CA 2147862 A1	11-05-1994
			EP 0668758 A1	30-08-1995
			JP 8502980 T	02-04-1996
			WO 9409762 A1	11-05-1994

